Just how much are Genentech trade secrets worth?

The storied South San Francisco biotech and Roche subsidiary unearthed a covert operation to profit from years of experience and knowhow when it accused Taiwan’s JHL Biotech of stealing information through one of its senior scientists. JHL, which had scored a pact with Sanofi to market biosimilars of Genentech’s top-selling drugs, has since settled the case and agreed to shut down any related work.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

One of the pioneers in the complete overhaul of oncology R&D over the last 10 years is headed to Amgen.

The pharma giant put out the word on social media that Jean-Charles Soria, the director general of the storied Gustave Roussy Institute in France, is joining LA-based Amgen to lead the oncology therapeutic area as senior vice president.

Soria, who also held a top oncology post with AstraZeneca before returning to the institute at the beginning of 2020, tells us via email that he is “deeply excited” to be joining the company.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Despite repeated calls to diversify the biotech industry, women and those in minority groups make up just 14% of board members at public micro- and small-cap companies, according to a new report by the Bedford Group and Transearch.

“Just the total percentage of CEOs [who] are female was much lower than anticipated,” said Darren Raycroft, partner and managing director at the Bedford Group.

For over a decade, the firm has compiled executive compensation reports in other verticals. But for the first time, they’re releasing a report based on 225 public biotech companies in the US with market caps under $2 billion — and what they found was a stark lack of diversity among the highest ranks of the industry.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

When Susan Galbraith joined the cancer R&D team at AstraZeneca in 2010, the pharma giant was undergoing a brutal takedown at the hands of analysts uniformly shaking their heads over one of the weakest pipelines among the majors. Both she and the company persevered, though, and went on to pioneer some of the most successful drug franchises in oncology.

Today, she takes her place as the new EVP of oncology research at AstraZeneca’s new research and development home in Cambridge, UK.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Karen Flynn came aboard Catalent’s team just in time.

The company was going through a surge of changes, and she had been brought over from her role as CCO of West Pharmaceutical Services to serve in the same capacity for the New Jersey-based CDMO. Then a few months later, the pandemic was in full-force.

Since then, Catalent’s been in hyper-expansion mode. In early May, it acquired Promethera’s Hepatic Cell Therapy Support SA subsidiary and its 32,40-square-foot facility in Gosselies, Belgium. Prior to that, the company acquired Belgian CDMO Delphi Genetics, wrapped up the expansion of an already-existing site in Madison, WI and added an ultra-low temperature freezer partner in Sterling. As Emergent has botched millions of doses of AstraZeneca’s vaccine, the company has swooped in to move that production to its Maryland plant as well.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Months after Galapagos cut away broad swaths of its pipeline following a rejection for Gilead-partnered rheumatoid arthritis drug filgotinib, the biotech will now say goodbye to its longtime chief scientific officer as it considers its options moving ahead.

Piet Wigerinck will step down from his role later this year, the company announced on Tuesday. Wigerinck joined in 2008 as the SVP of development, and became the CSO in 2012. He oversaw the discovery of novel targets through to clinical proof-of-concept studies, led the first clinical research in healthy volunteers and was responsible for two Phase II programs for filgotinib, a JAK inhibitor.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN